A Phase 1/2 Safety and Efficacy Study of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1876-202

To Learn More Call
(201)-510-0950